Page 122 - Škrgat, Sabina, ed. 2022. Severe Asthma - Basic and Clinical Views. Koper: University of Primorska Press. Severe Asthma Forum, 1
P. 122
Res. 2018 Jun 8;19(1):113. doi: 10.1186/ 8;20(1):179. doi: 10.1186/s12931-019-
s12931-018-0813-0. 1138-3.
severe asthma forum 1: severe asthma - basic and clinical views 25. Izuhara K, Nunomura S, Nanri Y, et 35. Hanania NA, Wenzel S, Rosén K,
al. Periostin in inflammation and al- et al. Exploring the effects of omali-
lergy. Cell Mol Life Sci. 2017; 74(23): zumab in allergic asthma: an analy-
4293-303. sis of biomarkers in the EXTRA study.
26. Rupani H, Chauhan AJ. Measurement Am J Respir Crit Care Med. 2013 Apr
of FeNO in asthma: what the hospital 15;187(8):804-11.
doctor needs to know? Br J Hosp Med 36. Humbert M, Taillé C, Mala L, et
(Lond). 2019 Feb 2;80(2):99-104. al. Omalizumab effectiveness in pa-
27. Arnold RJ, Massanari M, Lee TA , et tients with severe allergic asthma ac-
al. A Review of the Utility and Cost Ef- cording to blood eosinophil count:
fectiveness of Monitoring Fractional the STELLAIR study. Eur Respir
Exhaled Nitric Oxide (FeNO) in Asth- J. 2018 May 10;51(5):1702523. doi:
ma Management. Manag Care. 2018 10.1183/13993003.02523-2017.
Jul;27(7):34-41. 37. Varricchia G, Giorgio W. Canonica
28. Wenzel S. Severe asthma: from char- GW. The role of interleukin 5 in asth-
acteristics to phenotypes to endotypes. ma. Expert rev clin immunol. 2016
Clin Exp Allergy. 2012 May;42(5):650- Sep;12(9):903-5.
8. 38. Ortega HG, Liu MC, Pavord ID, et
29. Coumou H, Westerhof GA, de al. Mepolizumab treatment in patients
Nijs SB, et al. Predictors of accel- with severe eosinophilic asthma. N Engl
erated decline in lung function in J Med. 2014 Sep 25;371(13):1198-207.
adult-onset asthma. Eur Respir J. 39. Castro M, Zangrilli J, Wechsler ME, et
2018 Feb 14;51(2):1701785. doi: al. Reslizumab for inadequately con-
10.1183/13993003.01785-2017. trolled asthma with elevated blood eo-
30. Gauthier M, Ray A, Wenzel SE. sinophil counts: results from two mul-
Evolving concepts of asthma. Am ticentre, parallel, double-blind, ran-
J Respir Crit Care Med. 2015 Sep domised, placebo-controlled, phase
15;192(6):660-8. 3 trials. Lancet Respir Med. 2015
31. Thomson NC, Chaudhuri R. Omali- May;3(5):355-66.
zumab: Clinical Use for the Manage- 40. Pelaia C, Busceti MT, Vatrella A, et al.
ment of Asthma. Clin Med Insights Real-life rapidity of benralizumab ef-
Circ Respir Pulm Med. 2012;6:27-40 fects in patients with severe allergic eo-
32. Busse WW, Morgan WJ, Gergen PJ, et sinophilic asthma: Assessment of blood
al. Randomized trial of omalizumab eosinophils, symptom control, lung
(anti-IgE) for asthma in inner-city chil- function and oral corticosteroid intake
dren. N Engl J Med. 2011;364(11):1005- after the first drug dose. Pulm Phar-
15. macol Ther. 2019 Oct;58:101830. doi:
33. Taichman DB.Biologic therapies for se- 10.1016/j.pupt.2019.101830.
vere astme. N Engl J Med. 2022 Jan 13; 41. Wenzel S, Castro M, Corren J, et al.
386(2):157-71. Dupilumab efficacy and safety in adults
34. Edris A, De Feyter S, Maes T, et al. with uncontrolled persistent asthma de-
Monoclonal antibodies in type 2 asth- spite use of medium- to-high-dose in-
ma: a systematic review and network haled corticosteroids plus a long-acting
meta-analysis. Respir Res. 2019 Aug β2 agonist: a randomised double-blind
placebo-controlled pivotal phase 2b
s12931-018-0813-0. 1138-3.
severe asthma forum 1: severe asthma - basic and clinical views 25. Izuhara K, Nunomura S, Nanri Y, et 35. Hanania NA, Wenzel S, Rosén K,
al. Periostin in inflammation and al- et al. Exploring the effects of omali-
lergy. Cell Mol Life Sci. 2017; 74(23): zumab in allergic asthma: an analy-
4293-303. sis of biomarkers in the EXTRA study.
26. Rupani H, Chauhan AJ. Measurement Am J Respir Crit Care Med. 2013 Apr
of FeNO in asthma: what the hospital 15;187(8):804-11.
doctor needs to know? Br J Hosp Med 36. Humbert M, Taillé C, Mala L, et
(Lond). 2019 Feb 2;80(2):99-104. al. Omalizumab effectiveness in pa-
27. Arnold RJ, Massanari M, Lee TA , et tients with severe allergic asthma ac-
al. A Review of the Utility and Cost Ef- cording to blood eosinophil count:
fectiveness of Monitoring Fractional the STELLAIR study. Eur Respir
Exhaled Nitric Oxide (FeNO) in Asth- J. 2018 May 10;51(5):1702523. doi:
ma Management. Manag Care. 2018 10.1183/13993003.02523-2017.
Jul;27(7):34-41. 37. Varricchia G, Giorgio W. Canonica
28. Wenzel S. Severe asthma: from char- GW. The role of interleukin 5 in asth-
acteristics to phenotypes to endotypes. ma. Expert rev clin immunol. 2016
Clin Exp Allergy. 2012 May;42(5):650- Sep;12(9):903-5.
8. 38. Ortega HG, Liu MC, Pavord ID, et
29. Coumou H, Westerhof GA, de al. Mepolizumab treatment in patients
Nijs SB, et al. Predictors of accel- with severe eosinophilic asthma. N Engl
erated decline in lung function in J Med. 2014 Sep 25;371(13):1198-207.
adult-onset asthma. Eur Respir J. 39. Castro M, Zangrilli J, Wechsler ME, et
2018 Feb 14;51(2):1701785. doi: al. Reslizumab for inadequately con-
10.1183/13993003.01785-2017. trolled asthma with elevated blood eo-
30. Gauthier M, Ray A, Wenzel SE. sinophil counts: results from two mul-
Evolving concepts of asthma. Am ticentre, parallel, double-blind, ran-
J Respir Crit Care Med. 2015 Sep domised, placebo-controlled, phase
15;192(6):660-8. 3 trials. Lancet Respir Med. 2015
31. Thomson NC, Chaudhuri R. Omali- May;3(5):355-66.
zumab: Clinical Use for the Manage- 40. Pelaia C, Busceti MT, Vatrella A, et al.
ment of Asthma. Clin Med Insights Real-life rapidity of benralizumab ef-
Circ Respir Pulm Med. 2012;6:27-40 fects in patients with severe allergic eo-
32. Busse WW, Morgan WJ, Gergen PJ, et sinophilic asthma: Assessment of blood
al. Randomized trial of omalizumab eosinophils, symptom control, lung
(anti-IgE) for asthma in inner-city chil- function and oral corticosteroid intake
dren. N Engl J Med. 2011;364(11):1005- after the first drug dose. Pulm Phar-
15. macol Ther. 2019 Oct;58:101830. doi:
33. Taichman DB.Biologic therapies for se- 10.1016/j.pupt.2019.101830.
vere astme. N Engl J Med. 2022 Jan 13; 41. Wenzel S, Castro M, Corren J, et al.
386(2):157-71. Dupilumab efficacy and safety in adults
34. Edris A, De Feyter S, Maes T, et al. with uncontrolled persistent asthma de-
Monoclonal antibodies in type 2 asth- spite use of medium- to-high-dose in-
ma: a systematic review and network haled corticosteroids plus a long-acting
meta-analysis. Respir Res. 2019 Aug β2 agonist: a randomised double-blind
placebo-controlled pivotal phase 2b
